Author ORCID Identifier

Halie M. Rando: 0000-0001-7688-1770

Nils Wellhausen: 0000-0001-8955-7582

Soumita Ghosh: 0000-0002-2783-2750

Alexandra J. Lee: 0000-0002-0208-3730

Anna Ada Dattoli: 0000-0003-1462-831X

Fengling Hu: 0000-0003-1081-5038

James Brian Byrd: 0000-0002-0509-3520

Diane N. Rafizadeh: 0000-0002-2838-067X

Ronan Lordan: 0000-0001-9668-3368

Christian Brueffer: 0000-0002-3826-0989

Marouen Ben Guebila: 0000-0001-5934-966X

Nafisa M. Jadavji: 0000-0002-3557-7307

Ashwin N. Skelly: 0000-0002-1565-3376

Bharath Ramsundar: 0000-0001-8450-4262

Simina M. Boca: 0000-0002-1400-3398

Anthony Gitter: 0000-0002-5324-9833

Casey S. Greene: 0000-0001-8713-9213

Document Type

Article

Publication Date

12-1-2021

Publication Title

mSystems

Abstract

After emerging in China in late 2019, the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread worldwide, and as of mid- 2021, it remains a significant threat globally. Only a few coronaviruses are known to infect humans, and only two cause infections similar in severity to SARS-CoV-2: Severe acute respiratory syndrome-related coronavirus, a species closely related to SARS-CoV-2 that emerged in 2002, and Middle East respiratory syndrome-related coronavirus, which emerged in 2012. Unlike the current pandemic, previous epidemics were controlled rapidly through public health measures, but the body of research investigating severe acute respiratory syndrome and Middle East respiratory syndrome has proven valuable for identifying approaches to treating and preventing novel coronavirus disease 2019 (COVID-19). Building on this research, the medical and scientific communities have responded rapidly to the COVID-19 crisis and identified many candidate therapeutics. The approaches used to identify candidates fall into four main categories: adaptation of clinical approaches to diseases with related pathologies, adaptation based on virological properties, adaptation based on host response, and data-driven identification (ID) of candidates based on physical properties or on pharmacological compendia. To date, a small number of therapeutics have already been authorized by regulatory agencies such as the Food and Drug Administration (FDA), while most remain under investigation. The scale of the COVID-19 crisis offers a rare opportunity to collect data on the effects of candidate therapeutics. This information provides insight not only into the management of coronavirus diseases but also into the relative success of different approaches to identifying candidate therapeutics against an emerging disease. IMPORTANCE The COVID-19 pandemic is a rapidly evolving crisis. With the worldwide scientific community shifting focus onto the SARS-CoV-2 virus and COVID-19, a large number of possible pharmaceutical approaches for treatment and prevention have been proposed. What was known about each of these potential interventions evolved rapidly throughout 2020 and 2021. This fast-paced area of research provides important insight into how the ongoing pandemic can be managed and also demonstrates the power of interdisciplinary collaboration to rapidly understand a virus and match its characteristics with existing or novel pharmaceuticals. As illustrated by the continued threat of viral epidemics during the current millennium, a rapid and strategic response to emerging viral threats can save lives. In this review, we explore how different modes of identifying candidate therapeutics have borne out during COVID-19.

Keywords

COVID-19, Review, Therapeutics

Volume

6

Issue

6

DOI

10.1128/mSystems.00233-21

Comments

Archived as published.

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.